LONDON--(BUSINESS WIRE)--Technavio has announced their latest drug pipeline analysis report on juvenile idiopathic arthritis. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat juvenile idiopathic arthritis.
This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Juvenile idiopathic arthritis: Market overview
Juvenile idiopathic arthritis (JIA) also known as a pediatric rheumatic disease, is the most common type of arthritis found in children under the age of 16 years. Some children may experience symptoms for only a few months, while others have symptoms for the rest of their lives. JIA affects the body tissues of the child, leading to painful inflammation in joints. Currently, there is no cure for JIA, however, with early diagnosis and treatment, the remission of JIA is under control.
According to a senior market research analyst at Technavio, “The National Institutes of Health stated in their research that the incidence of JIA in North America and Europe is estimated to be 4-16 in 10,000 children. In the US alone, one in 1,000 children is affected, which is estimated to be 294,000 children. Globally, the incidence rate of JIA varies across various populations and ethnic groups.”
Juvenile idiopathic arthritis: Segmentation analysis
This pipeline analysis report segments the juvenile idiopathic arthritis market based on therapies employed (monotherapy and combination therapy), RoA (oral, subcutaneous, intravenous, and intravenous and subcutaneous), therapeutic modalities (monoclonal antibody, small molecule, and recombinant protein), targets (TNF-α, IL-6, JAK, IFN γ, IL-17A, IL-1RI, and IL-18BP), MoA (TNF-α inhibitor, IL-6 antagonist, JAK inhibitor, IFN γ inhibitor, IL-17A inhibitor, IL-1RI antagonist, and IL-18BP inhibitor), geographical segmentation (US, Mexico, Russian Federation, Canada, Argentina and others) and recruitment status (active, not recruiting, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on therapeutic modality, more than 69% of the molecules that are being investigated for the treatment of juvenile idiopathic arthritis are monoclonal antibodies.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- Therapeutic modality
- Geographical coverage
- Recruitment status
- Type of players
- Company overview
Discontinued or Dormant Molecules
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.